Bridge Medicines appoints William J. Polvino as Chief Executive Officer
As Chief Executive Officer of the newly formed drug discovery company, founded by Rockefeller University and its two neighboring institutions, Polvino will be responsible for building a portfolio of early-stage drug discovery projects and advancing each program from animal proof of principle to clinical trials. More »
Source: The Rockefeller University Newswire - Category: Biomedical Science Authors: Katie Fenz Tags: Campus News Bridge Medicines drug discovery Tri-I TDI William J. Polvino Source Type: news
More News: Biomedical Science | Clinical Trials